Document Detail

The combined use of sodium valproate and metyrapone in the treatment of Cushing's syndrome.
MedLine Citation:
PMID:  2847889     Owner:  NLM     Status:  MEDLINE    
We have investigated the combined use of metyrapone and sodium valproate in the treatment of five cases of dexamethasone-suppressible Cushing's disease and one case with dexamethasone non-suppressible disease. Metyrapone alone reduced 24 h urinary free cortisol (UFC) and plasma cortisol concentrations. Addition of sodium valproate to metyrapone produced a further reduction in these values in five of six patients with a reduction in plasma ACTH in three of five patients who had dexamethasone-suppressible disease. Plasma 11-deoxycortisol increased markedly on metyrapone. However, addition of valproate produced a further rise in 11-deoxycortisol values in four of five patients including the patient with dexamethasone non-suppressible disease. The results suggest that valproate may be a useful addition to metyrapone in the medical treatment of some patients with Cushing's syndrome and that it may have an action both at the hypothalamus and peripherally.
S S Nussey; P Price; J S Jenkins; A R Altaher; B Gillham; M T Jones
Related Documents :
12566729 - Growth hormone (gh) secretion in patients with childhood-onset gh deficiency: retesting...
18072409 - Prospective evaluation and characteristics of patients with suspected primary hyperaldo...
15879359 - Evaluation of adrenal function in patients with growth hormone deficiency and hypothala...
3818889 - Adrenal and steroidal cell antibodies in patients with autoimmune polyglandular disease...
3118729 - Growth hormone response to grf 1-44 in children following cranial irradiation for centr...
17524029 - Long-term (up to 18 years) effects on gh/igf-1 hypersecretion and tumour size of primar...
15190959 - Association between surfactant protein b + 1580 polymorphism and the risk of respirator...
8761039 - Postexcitatory inhibition after transcranial magnetic single and double brain stimulati...
25456879 - Predictors of natriuretic peptide non-response in patients hospitalized with acute hear...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical endocrinology     Volume:  28     ISSN:  0300-0664     ISO Abbreviation:  Clin. Endocrinol. (Oxf)     Publication Date:  1988 Apr 
Date Detail:
Created Date:  1988-12-28     Completed Date:  1988-12-28     Revised Date:  2009-09-29    
Medline Journal Info:
Nlm Unique ID:  0346653     Medline TA:  Clin Endocrinol (Oxf)     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  373-80     Citation Subset:  IM    
Department of Medicine, St George's Hospital Medical School, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenocorticotropic Hormone / blood
Cortodoxone / blood
Cushing Syndrome / drug therapy*,  metabolism
Drug Therapy, Combination
Hydrocortisone / metabolism
Middle Aged
Pyridines / therapeutic use*
Valproic Acid / therapeutic use*
Grant Support
//Wellcome Trust
Reg. No./Substance:
0/Pyridines; 152-58-9/Cortodoxone; 17286-92-9/metapyrone; 50-23-7/Hydrocortisone; 9002-60-2/Adrenocorticotropic Hormone; 99-66-1/Valproic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Alpha-adrenergic receptor stimulation during simulated ischemia and reperfusion in canine cardiac Pu...
Next Document:  IgG subclass distribution of antiviral antibodies in common variable immunodeficiency: effect of sub...